Abionyx Pharma (STU:609) FFO


STU:609 Abionyx Pharma STU:609
23 GF Score
Price €1.84
GF Value €0.75
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Abionyx Pharma FFO?

FFO (Funds from operations) only applies to REITs.

STU:609
23GF Score
Abionyx Pharma STU:609
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Abionyx Pharma (STU:609) Overvalued in 2026?

Based on GuruFocus' analysis, Abionyx Pharma stock appears to be overvalued. The current stock price of €1.84 is trading 145.1% above its estimated GF Value™ of €0.75. GuruFocus considers Abionyx Pharma to be Significantly Overvalued.

Key valuation signals for STU:609:

  • FFO:
  • GF Value™: €0.75 vs. price of €1.84 (145.1% above fair value)
  • GF Score™: 23/100 with 4 warning signs

No single metric tells the full story. See the STU:609 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Abionyx Pharma Business Description

Other Exchanges 0RAG:UKABNX:France
Address 33-43 Avenue Georges Pompidou-Bat D2, Balma, FRA, 31130
Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.
23GF Score

Get the complete analysis for STU:609

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.84
Price
€0.75
GF Value